Publicaciones en las que colabora con Pompeyo Viciana (28)

2022

  1. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial

    Stem Cells Translational Medicine, Vol. 10, Núm. 4, pp. 534-541

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice

    Journal of Acquired Immune Deficiency Syndromes, Vol. 81, Núm. 1, pp. E1-E5

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  3. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

    PLoS ONE, Vol. 13, Núm. 9

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  3. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

  4. Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract

    Clinical Microbiology and Infection, Vol. 22, Núm. 1, pp. 98.e7-98.e10

2014

  1. Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT

    Revista Espanola de Quimioterapia, Vol. 27, Núm. 2, pp. 93-97

  2. Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population

    PLoS ONE, Vol. 9, Núm. 5

  3. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  4. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2010

  1. Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: A multicentre prospective study

    AIDS Research and Therapy, Vol. 7

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230